Zenith Epigenetics Ltd. announced the execution of a cooperative research and development agreement with the National Cancer Institute to develop ZEN-3694 for multiple oncology indications. For the first clinical study under the CRADA, NCI is co-collaborating with Zenith and Bristol Myers Squibb to investigate the combination of Zenith’s epigenetic therapy BET inhibitor ZEN-3694 with immuno-oncology therapies – checkpoint inhibitors nivolumab and ipilimumab – in resistant ovarian cancer.